Table 2 Patient characteristics

From: Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

 

Total N =55

Variable

N (%)

Sex

 Male

34 (62)

 Female

21 (38)

Median age, years (range)

59 (20–81)

ECOG performance status

 0

24 (43)

 1

22 (40)

 2

5 (9)

 3

2 (4)

 Unknown

2 (4)

Tumour type

 Clear cell

48 (87)

 Other

7 (13)

Previous nephrectomy

45 (82)

Prior treatment

 None

15 (27)

 Cytokine based-therapy

40 (73)

 Anti-angiogenic therapy

4 (7)

No. of disease sites

 1

7(13)

 2

20 (36)

 ⩾3

28 (51)

Sites of disease

 Lung

49 (89)

 Lymph nodes

32 (58)

 Bone

13 (24)

 Liver

11 (20)

 Local recurrence

7 (13)

 Brain

4 (7)

MSKCC risk groups a

 0 (favourable)

11 (20)

 1–2 (intermediate)

36 (65)

 ⩾3 (poor)

7 (13)

 Unknown

1 (2)

  1. Abbreviations: ECOG=Eastern Cooperative Oncology Group; MSKCC=Memorial Sloan-Kettering Cancer Center.
  2. aRisk groups according to MSKCC prognostic criteria (based on the 5 risk factors: low Karnofsky performance status (<80%), high LDH (>1.5 times the upper limit of normal), low serum haemoglobin, high corrected serum calcium (>10 mg per 100 ml), and time from initial diagnosis to treatment of less than 1 year) (Motzer et al, 2002).
Back to article page